Abstract: Methods, devices and systems for Transcranial Magnetic Stimulation (TMS) are provided for synchronous, asynchronous, or independent triggering the firing multiple of electromagnets from either a single power source or multiple energy sources. These methods are particularly useful for stimulation of deep (e.g., sub-cortical) brain regions, or for stimulation of multiple brain regions, since controlled magnetic pulses reaching the deep target location may combine to form a patterned pulse train that activates the desired volume of target tissue. Furthermore, the methods, devices and systems described herein may be used to control the rate of firing of action potentials in one or more brain regions, such as slow or fast rate rTMS. For example, described herein are multiple electromagnetic stimulation sources, each of which are activated independently to create a cumulative effect at the intersections of the electromagnetic stimulation trajectories, typically by means of a computerized calculation.

Abstract: Described herein are Transcranial Magnetic Simulation (TMS) systems and methods of using them for emitting focused, or shaped, magnetic fields for TMS. In particular, described herein are arrays of TMS electromagnets comprising at least one primary (e.g., central) TMS electromagnet and a plurality of secondary (e.g., lateral or surrounding) TMS electromagnets. The secondary TMS electromagnets are arranged around the primary TMS electromagnet(s), and are typically configured to be synchronously fired with the primary TMS electromagnets. Secondary TMS electromagnets may be fired at a fraction of the power used to energize the primary TMS electromagnet to shape the resulting magnetic field. The secondary TMS electromagnets may be stimulated at opposite polarity to the primary TMS electromagnet(s). Focusing in this manner may prevent or reduce stimulation of adjacent non-target brain regions.

Abstract: Cells and cell lines that are genetically modified to express the hCox-2 enzyme, which results in the upregulation of prostaglandin F2 alpha (PGF2a) on the cells have been obtained. Encapsulated cell therapy devices containing such cells or cell lines that are capable of delivering PGF2a, as well as methods of using these devices to deliver PGF2a to the eye and to treat ophthalmic disorders in patients suffering therefrom are also described.

Abstract: Systems and methods for modulating deep brain target regions using an array of TMS electromagnets, wherein each TMS electromagnet stimulates the target at a level that is below motor threshold (MT). Neurological disorders (or disorders having neurological effects) may be treated by sub-MT stimulation of deep-brain targets from an array of TMS electromagnets.

Abstract: Described herein are shaped coil TMS electromagnets formed by two bent magnetic coil loops joined at a vertex having an angle between the outer coil regions of the coils that is typically less than 120 degrees (e.g., between about 45 and about 70 degrees, 60 degrees, etc.). The vertex region shaped to optimize the magnetic field projected from the TMS electromagnet. For example, the vertex region may be horizontal or vertical. In some variations the vertex region is formed by re-arranging the conductive windings forming the two coils so that they are no longer arranged in the same columnar structure that they are in the other portions of the bent magnetic coil loops. These TMS electromagnets may be well suited for use in deep-brain Transcranial Magnetic Stimulation.

Abstract: The present invention provides an efficient method for mass-producing 2-hydroxy-5-(substituted)phenylalkylamino benzoic acid derivatives represented by specific Chemical formulas or their salts, particularly 2-hydroxy-5-[2-(4-trifluoromethylphenyl)ethylamino]benzoic acid or its salt.

Abstract: The present invention provides a method of determining a treatment program for a subject. The method includes obtaining subject data representing the subject's condition. The subject data is used together with a model of the condition, to determine system values representing the condition. These system values are then used to determining one or more trajectories representing the progression of the condition in accordance with the model. From this, it is possible to determine a treatment program in accordance with the determined trajectories.

Abstract: The present invention relates to a pharmaceutical composition useful for treating or preventing inflammatory disease and cell damage, and a method for treating or preventing inflammatory disease and cell damage. The present invention uses the 2-hydroxybenzoic acid derivative represented by the specific chemical formula or its pharmaceutically acceptable salt. The compound of the present invention is useful for treating or preventing cell damage and inflammatory disease including gastritis, gastric ulcer, pancreatitis, colitis, arthritis, diabetes, arteriosclerosis, nephritis, hepatitis, Alzheimer's disease, Parkinson's disease and Lou Gehrig's disease.

Abstract: The present invention relates to a pharmaceutical composition useful for treating or preventing inflammatory disease and cell damage, and a method for treating or preventing inflammatory disease and cell damage. The present invention uses the 2-hydroxybenzoic acid derivative represented by the specific chemical formula or its pharmaceutically acceptable salt. The compound of the present invention is useful for treating or preventing cell damage and inflammatory disease including gastritis, gastric ulcer, pancreatitis, colitis, arthritis, diabetes, arteriosclerosis, nephritis, hepatitis, Alzheimer's disease, Parkinson's disease and Lou Gehrig's disease.

Abstract: Described herein are methods for neuromodulating brain activity of one or more target brain regions, the methods using Transcranial Magnetic Stimulation (TMS) to produce robust analgesia. In particular, described herein are systems for arranging one or more (e.g., a plurality) of TMS electromagnets oriented in a transverse direction, perpendicular to the posterior-anterior axis of the head, and applying sufficient energy to neuromodulate the target deep brain region.

Abstract: The present disclosure discloses an apparatus to be implanted in eyes, including: a configuration memory used for storing signal parameter configuration; a signal generator connected to the configuration memory and used for generating stimulating signals according to the signal parameter configuration in the configuration memory; electrodes connected to the signal generator and contact with outer surface of eye ball after implanted; a communication assembly connected to the configuration memory and used for receiving the signal parameter configuration, storing the received signal parameter configuration in the configuration memory; and a power supply connected to the configuration memory, signal generator and communication assembly, used for providing power. An update system for the apparatus is also disclosed.

Abstract: The treatment of specific neurological and psychiatric illnesses using Transcranial Magnetic Stimulation (TMS) requires that specific neuroanatomical structures are targeted using specific pulse parameters. Described herein are methods of positioning and powering TMS electromagnets to selectively stimulate a deep brain target region while minimizing the impact on non-target regions between the TMS electromagnet and the target. Use of these configurations may involve a combination of physical, spatial and/or temporal summation. Specific approaches to achieving temporal summation are detailed.

Abstract: The invention relates to a method of diagnosing or monitoring schizophrenia or other psychotic disorder.

Abstract: The invention relates to a method of diagnosing or monitoring major depressive disorder using MMP-3 as a biomarker.

Abstract: The present invention relates to a pharmaceutical composition useful for treating or preventing inflammatory disease and cell damage, and a method for treating or preventing inflammatory disease and cell damage. The present invention uses the 2-hydroxybenzoic acid derivative represented by the specific chemical formula or its pharmaceutically acceptable salt. The compound of the present invention is useful for treating or preventing cell damage and inflammatory disease including gastritis, gastric ulcer, pancreatitis, colitis, arthritis, diabetes, arteriosclerosis, nephritis, hepatitis, Alzheimer's disease, Parkinson's disease and Lou Gehrig's disease.

Abstract: The present invention relates to a compliant deformable conductor and a method for producing the same, comprising a wire or a tube made of an electrically insulating material and one or more electrical leads applied on said wire or tube, wherein one or more of said leads comprise a plurality of islets of conductive material, forming an electrically conductive layer providing electrical conduction and/or electrical percolation.

Abstract: The invention relates to a method of diagnosing or monitoring schizophrenia or other psychotic disorder. The biomarkers used are selected from cyclophilin A, cytosalic non-specific dipepditase, Caoctosin-like protein, Glucose-6-phosphate isomerase, uncharacterized protein KIAA0423, myosin 14, myosin 15, nicotinamide phosphoribosyltransferase, pyruvate kinase isozyme R/L, phosphoglyterate mutase 4.

Abstract: The invention relates to a method of diagnosing or monitoring schizophrenia or other psychotic disorder.

Abstract: The invention relates to a method of diagnosing or monitoring schizophrenia or other psychotic disorder.

Abstract: The invention relates to a method of diagnosing or monitoring schizophrenia or other psychotic disorder.